why would someone not lose weight on semaglutide Am I Losing Semaglutide: Medical Causes Explained Semaglutide Non-Response: Why Some Don't

Semaglutide is a medication that belongs to the class of drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists

The GLP-1 Race Is No Longer About the Molecule Its About Delivery On January 12, 2026, Chinas CDE approved Shiling Pharmas Semaglutide Nasal Spray for clinical trials in long-term weight managementmarking the worlds first mucosal GLP-1 therapy (Class 2.2 innovation)

At USD 1,349 per month list price for Wegovy and USD 1,059 for Zepbound, monthly GLP-1 obesity drug costs create absolute financial barriers for the 62% of obesity patients enrolled in Medicaid, Medicare, or underinsured commercial plans without anti-obesity medication benefits

Troubleshoot aggregation and precipitation early, and verify concentration with lab methods when accuracy counts

The backstory: CVS Caremark, the nations largest pharmacy benefit manager, stopped covering Zepbound on July 1, 2025, after reaching a deal with Novo Nordisk, the maker of rival GLP-1 drug Wegovy